跳至主要内容
临床试验/NCT00645736
NCT00645736已完成不适用

Study of Acquired Viral Mutations in Chronic Hepatitis B Patients on Antihepadnaviral Therapy

Gilead Sciences1 个研究点 分布在 1 个国家目标入组 788 人开始时间: 2008年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
788
试验地点
1
主要终点
Descriptive statistics for clinical and viral characteristics of the study population

研究概览

简要总结

This study has the aim of describing viral mutation profiles in patients diagnosed with chronic hepatitis B receiving antihepadnaviral therapy.

详细描述

This is a naturalistic cross-sectional study of chronic hepatitis B subjects receiving nucleoside or nucleotide antihepadnaviral therapy.

It is anticipated approximately 800 subjects will be recruited at 20 Australian sites. Data will be collected on the study subjects and analyses performed to describe factors contributing to the emergence of viral mutations in Australian patients with chronic hepatitis B.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 18 years and over
  • Provided informed consent
  • Diagnosis of chronic hepatitis B (HBsAg documented for at least 6 months)
  • Currently prescribed antihepadnaviral therapy (including, but not limited to: lamivudine, adefovir, entecavir, tenofovir or telbivudine) for chronic hepatitis B management
  • Been taking current antihepadnaviral therapy for at least 6 months prior to recruitment
  • Negative tests for HIV Ab, Hepatitis C Ab and Hepatitis D Ab within the previous 2 years

排除标准

  • Known or suspected co-infection with HIV, Hepatitis C or Hepatitis D
  • Concomitant immunosuppression / immunomodulatory therapies
  • Diagnosis of hepatocellular carcinoma where anticipated life expectancy is less than 6 months
  • Current participation in an interventional, blinded, pharmaceutical industry-sponsored clinical trial
  • Current Child Pugh class C classification (current Child Pugh score > 9)
  • Other known or suspected cause of chronic liver disease
  • Any other reason that, in the investigator's opinion, participation in the study would not be in the participant's best interest.

结局指标

主要结局

Descriptive statistics for clinical and viral characteristics of the study population

时间窗: Single timepoint (blood draw)

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

CHARM: Chronic Hepatitis B Antihepadnaviral... | 临床试验